More than 55 million people worldwide suffer from dementia. Alzheimer disease (AD) is the main cause of this fatal disorder, without any effective disease modifying therapy. Early diagnosis and lifestyle modifications can significantly reduce the costs of care and treatment. There is no conceptual plan implementing modern diagnostic methods in the clinical practice in Czechia and Slovakia. The interaction between universities and private sector developing molecular diagnostic tools is fragmented and lacking. Limited number of talented students are invested in applied AD-focused research. The aim of ADDIT-CE is to interlink two ecosystems in Brno and Bratislava region, embracing the full quadruple helix of innovation driving actors: excellent scientific teams from Masaryk University and Slovak Academy of Sciences, collaborating with top biotech companies: Geneton, BioVendor, and MultiplexDX. Societal actors will be represented by organisations such as Slovak and Czech Alzheimer Societies, Memory Center and Czech Brain Aging Study. The regional government will be involved via Ministry of Health Slovak Republic, and South Moravian Innovation Centre. The joined ecosystems will unite R&I activities focusing on new diagnostic methods and their applications and further interlink academia and business spheres by creating a pilot industrial PhD programme. ADDIT-CE will generate a joint cross-border strategy covering basic and applied research activities aiming on accelerating the development of new tools for preclinical AD diagnostics and lifestyle/pharmacological intervention monitoring. New cutting-edge technologies will be transferred into clinical practise. Results of ADDIT-CE will be used to develop the Slovak National Plan to Combat Dementia, to enrich the Czech National Plan for AD, and will be widely disseminated to end users and society. ADDIT-CE will join forces of the involved ecosystems to revolutionise diagnostic approaches in both countries.